Semaglutide
Long-acting GLP-1 analogue approved for type-2 diabetes and chronic weight management. The most rigorously studied peptide on this index.
Start with a product
Pick what you have. We'll guide the rest.
Schedule, what to expect, side-effects to watch — built around your exact product.
Also: Ozempic · Wegovy · Rybelsus
Long-acting GLP-1 analogue approved for type-2 diabetes and chronic weight management. The most rigorously studied peptide on this index.
Evidence Intelligence Score™
- Preclinical
- Pilot human
- RCT← current
- Multi-RCT
- Meta-analysis
Confidence aggregates eight dimensions of evidence — human data, safety maturity, mechanism, clinical readiness, momentum, consistency, long-term follow-up, and translational signal. It is a measure of what is known, not a recommendation. Methodology.
- Human evidenceWeight of RCT and observational data9.4
- Safety maturityFollow-up depth and adverse-event signal6.1
- Mechanism confidencePathway specificity and clarity7.1
- Clinical readinessDistance to physician-prescribable use8.1
- Research momentumRecency of indexed clinical evidence9.3
- Study consistencyEffect direction across cohorts10.0
- Long-term dataFollow-up beyond initial trial windows5.4
- Translational confidenceAnimal → human signal preservation8.3
4 indexed clinical studies across 3 outcomes; signal currently reads moderate.
Effect sizes outside trial populations and durations beyond the studied window remain less characterized.
Interactions outside listed contraindications, long-term safety, and effect heterogeneity across age and sex are not fully resolved.
Outlook: tracked. The score above re-grades automatically as new indexed evidence is admitted.
Weight / fat reduction
5 studies- strongRubino DM, Greenway FL, Khalid U, et al.
Semaglutide 2.4 mg/wk -15.8% vs liraglutide 3.0 mg/d -6.4% at 68 weeks.
RCTn=3382022unreviewed - strongWilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al.RCTn=1,9612021
- strongWadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, et al.RCTn=6112021
- strongRubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al.RCTn=8032021
- moderateMarso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al.RCTn=3,2972016
Cardiometabolic health
2 studies- strongLincoff AM, Brown-Frandsen K, Colhoun HM, et al.
Semaglutide 2.4 mg/wk reduced MACE 20% (HR 0.80) over mean 39.8 mo in overweight/obese with prior CVD without diabetes.
RCTn=17,6042023unreviewed - strongMarso SP, Bain SC, Consoli A, et al.
Semaglutide reduced MACE 26% (HR 0.74) vs placebo over 2y in T2D.
RCTn=3,2972016unreviewed
Appetite & food-noise suppression
1 study- strongFriedrichsen M, Breitschaft A, Tadayon S, et al.
Semaglutide 2.4 mg reduced ad-libitum energy intake ~35% and lowered hunger/cravings vs placebo.
RCTn=722021unreviewed
Weight / fat reduction
2 regimensBoxed warning: thyroid C-cell tumors. Pancreatitis, gallbladder, hypoglycemia (with insulin/SU), AKI, retinopathy, suicidal-ideation surveillance.
Per Wegovy label — escalate every 4 wk; delay/lower step if not tolerated.
GI AEs predominant; more gallbladder events vs placebo.
68-wk study with reduced-calorie diet + 150 min/wk activity.
Cardiometabolic health
1 regimenAE discontinuation 16.6% vs 8.2% placebo, mostly GI.
Adults ≥45y, BMI ≥27, established CVD, no diabetes.
Appetite & food-noise suppression
1 regimenGI AEs predominant during titration.
Mechanistic crossover; ad-libitum energy intake at steady state.
These are observed research regimens drawn from approved labels, clinical trials, or preclinical literature — not dosing recommendations. Suggestive, never prescriptive.
- —Long-term safety beyond reported study durations.
- —Effect size in populations under-represented in the cited trials.
- —Interactions with concomitant medications outside listed contraindications.
We surface uncertainty next to every claim. Suggestive, never prescriptive — discuss with a clinician.
9 brands across three tiers.
Medicine
3 brandsRegulator-approved finished medicines. Prescribed for specific indications, manufactured under GMP, distributed through licensed pharmacies.
Compounded (US 503A)
4 brandsPatient-specific preparations from US 503A compounding pharmacies. Require a valid prescription, not FDA-approved as finished drugs. Check the pharmacy's licence and the active ingredient's status on the FDA 503A bulks list.
Research-use only
2 brandsSold by chemical suppliers labelled 'for laboratory research only — not for human consumption'. No pharmaceutical-grade QC, no medical oversight. Listed for transparency.